Laboratory Research Technician – Cell Culture & Immunology
As a Laboratory Research Technician, you will support the mission-critical daily research activities that keep our TCR-T cell programs moving forward.
Pan Cancer T’s potential recognised at MEET2WIN with two awards
June 15, 2025
On 5th-7th May, Pan Cancer T’s CEO, Rachel Abbott, attended the 10th edition of MEET2WIN, the European partnering convention dedicated to the fight against cancer. Organised by the French platform MATWIN (a 100% subsidiary of Unicancer), the event brought together more than 300 international stakeholders – researchers, major groups, biotechs, startups, investors, and support organizations – united by a shared ambition: to accelerate innovation in oncology.
Pan Cancer T was recognised with the Best Investment Potential award by the OUI (Oncology Upward Investment) jury, composed of around 15 European investors.
Additionally, Pan Cancer T received an award from the QUICK PITCH jury, composed of MATWIN board members and the full MEET2WIN audience. This gave Rachel the opportunity to give a more extensive presentation and receive feedback from the
prestigious MATWIN international board, comprising Oncology R&D decision-makers from academic experts from leading European cancer research centres and the 14 partner pharma companies (Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Exact Sciences, GlaxoSmithKline, insitro, MSD, Pierre Fabre, Pfizer, Sanofi, Servier, and Takeda).
Other news
Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer
Pan Cancer T has secured EUR 10 million to move its TCR T cell therapy for triple negative breast cancer into first-in-human trials
Pan Cancer T announces that Dr. Helen Tayton-Martin has joined its board as an independent director
Dr. Helen Tayton-Martin joins our board, bringing decades of leadership in TCR-T cell therapy and biotech growth.